Phase 4 N=113 Anti-HIV Medications for People Recently Infected With HIV
HIV Infections
Primary: Total Treatment-free Time to Initiation of Permanent HAART — 18; 18 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=46 A Key Link for Transmission Prevention
HIV
Primary: Proportion of Persons Agreeing to be Screened for Acute HIV Infection Among Those Offered Screening — 0.622 proportion of participants screened
Phase 3 N=33 Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet
HIV
Primary: Number of Participants With a Viral Load Measurement of <200 Copies/mL at Week 24 — 28 participants
Phase 4 N=92 Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)
Acute HIV Infection · HIV Infections
Primary: Number of Participants Without Virologic Failure at Week 24 — 81 Participants
Phase 2 N=195 Early ART to Limit Infection and Establishment of Reservoir
HIV-1 Infection
Primary: Proportion of Participants With Undetectable Cell-associated HIV-1 DNA (CAHD) — 0.00; 0.00; 0.00; 0.10 Proportion of participants — p=0.48
N/A N=40 Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection
HIV · Acute HIV Infection
Primary: Number of Participants With Viral Load Measurement <200 Copies/mL at Week 24 — 34 Participants
Phase 3 N=32 Effects of Intensive cART During Acute/Early HIV Infection
Acute HIV Infection
Primary: Change in Proviral HIV-1 DNA in Total CD4+ T-cells From Baseline to Week 48 in Participants Randomized to the Intensified Arm Versus the Control Arm Who Received Placebo…
Phase 4 N=21 Treatment of Acute Hepatitis C Virus in HIV Co-Infection
Hepatitis C · Human Immunodeficiency Virus · HIV Infections
Primary: Sustained Virologic Response (SVR) — 62 percentage of participants
N/A N=18 Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection
Acute HIV Infection
Primary: Mean White Blood Cell Count Between Treatment Groups at 2 Months — 5904; 4918 white blood cells per microliter (mcL).
Phase 4 N=225 HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women
HIV
Primary: Number of Participants With HIV Viral Load Suppression in Plasma — 2; 1; 84; 8 Participants
Phase 1 N=44 Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection
HIV-1 Infection · Hepatitis
Primary: Percentage of Participants With Sustained Virologic Response 12 (SVR12) — 58.8; 100.0 Percentage of participants
N/A N=16 Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 Infection
HIV Infections
Primary: Plasma HIV-1 Viral Load (Copies/ml) at Week 24 as Compared Between the Two Arms — 4.8627; 4.2620 Log 10 copies of virus/ml
N/A N=151 Modulating the Impact of Critical Events in Early HIV Infection: Effect of ART Initiation and Alcohol Use
HIV Infection
Primary: Baseline HIV DNA Reservoir: Total HIV DNA — 3.83; 3.67; 3.40 Log10 HIV DNA copies/10^6 CD4 T cells — p=0.048
N/A N=249 Tambua Mapema Plus - to Discover HIV Infection Early and Prevent Onward Transmission
HIV Infections
Primary: Proportion of Patients With Newly Diagnosed HIV Infection at Care Seeking — 50; 13; 37; 2 Participants
Phase 2 N=45 Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection
Hepatitis C Infection · HIV Infection
Primary: Percentage of Participants With Sustained Virologic Response at 12 Weeks Post Treatment Discontinuation (SVR12) — 84.4 percentage of participants
Phase 2 N=19 Safety and Therapeutic Efficacy of the VRC01 Antibody in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV Infection
HIV Infections
Primary: Number of Participants With Serious Adverse Event — 0; 0 Participants
Phase 2 N=14 A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults
HIV Infections
Primary: Part 1: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) at Day 11 — -8605.8; -100719.8; -3406.5 Copies per milliliter
N/A N=300 HIV HOspital TEsting: Bringing the Hidden to Light in the Hospital Setting
Hiv · HIV Infections · AIDS
Primary: Prevalence of HIV Infection — 6 Participants
Phase 1 N=24 Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection
HIV Infections
Primary: Number of Participants With Grade 3 or Greater mAb-related Reactogenicity and mAb-related Adverse Events (AEs) — 0; 0; 1 Participants
N/A N=215 Incidence of HANA Conditions in HIV-infected Individuals
HIV · Metabolic Syndrome · Osteopenia
Primary: Prevalences of HIV-associated Non-AIDS Conditions (HANA) — 69; 15; 30; 4 Participants — p=0.244
Phase 3 N=131 Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults
HIV Infections
Primary: Percentage of Participants With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) Regardless of Antiretroviral…
N/A N=9,572 HIV Screening in the Emergency Department Setting
HIV Infections
Primary: Percentage of Tested Participants Newly Diagnosed as HIV Infected — 6; 3 percentage of tested that are positive
N/A N=81 To Assess Neuroinflammation and Neurocognitive Function in Patients With Acute Hepatitis C and Chronic HIV Co-Infection
Acute Hepatitis C · HIV · HIV Infections
Primary: Association of 11C-labelled PK11195 Uptake Using PET With Acute HCV and HIV Infection — 0.18; 0.22 binding potential ratio
Phase 3 N=80 Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV
Acute Hepatitis C · Human Immunodeficiency Virus · Hepatitis C
Primary: SVR12 (Reinfection Not Considered Failure) — 79 participants
N/A N=322 HIV Oral Testing Infographic Experiment
HIV/AIDS
Primary: HIV Self-testing Knowledge — 3.24; 3.79 score on a scale
N/A N=120 HIV And Parasitic Infection (HAPI) Study
HIV Coinfection
Primary: Number of Participants With and Without Intestinal Parasitic Infection — 36; 84 Participants
Phase 1 N=16 Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic Adults
HIV-1
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 3 Days After VRC01LS or VRC07-523LS Administration — 7; 6; 0; 3 Participants
N/A N=88 GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women
Genital Herpes
Primary: Time to Healing of Genital Lesions — 5.1; 6.0 Days
Phase 1 N=10 A Phase 1 Trial to Evaluate CAP256V2LS in Healthy Adults
HIV
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of CAP256V2LS Product Administration — 5; 4; 0; 1 Participants
Phase 3 N=8,657 Evaluation of Diagnostic HIV Ag/Ab Combo Assay
Human Immunodeficiency Viruses
Primary: Architect HIV Combo Test Data for Clinical Specificity in Population at Low Risk for HIV Infection — 37; 14; 0; 6113 Blood Specimens